Ignite Creation Date:
2025-12-24 @ 7:23 PM
Ignite Modification Date:
2025-12-30 @ 12:26 AM
Study NCT ID:
NCT04790903
Status:
TERMINATED
Last Update Posted:
2024-07-11
First Post:
2021-03-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-07-02
Start Date Type:
ACTUAL
Primary Completion Date:
2024-05-21
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-05-21
Completion Date Type:
ACTUAL
First Submit Date:
2021-03-08
First Submit QC Date:
None
Study First Post Date:
2021-03-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-09
Last Update Post Date:
2024-07-11
Last Update Post Date Type:
ACTUAL